KRAS and colorectal carcinoma: Approximately 47% of the CRC samples with KRAS G13D mutations were recently suggested to have distinct therapy-based outcome characteristics [8] and were tracked with our KRAS WT samples in terms of having low PI3K signaling and a high HER1 expression.